STAND UP TO CANCER ANNOUNCES $1.5 MILLION COMMITMENT FROM PANCREATIC CANCER NORTH AMERICA TO FUND PANCREATIC CANCER VACCINE RESEARCH
Retrieved on:
Thursday, June 1, 2023
Vaccine, Messenger RNA, Memorial Sloan Kettering Cancer Center, Pancreatic cancer, Convergence research, COVID-19, Cancer, Hope, Research, Doctor of Philosophy, Messenger, Collaborative RESearch Team to study psychosocial issues in Bipolar Disorder, MD, Patient, Immune system, SU2C, MSK, Mortality, PCNA, Pharmaceutical industry
The vaccine developed for the trial was tailored to recognize the cancer cells present in each trial participant's pancreatic cancer tumor and stimulate the body's immune system to fight the cancer.
Key Points:
- The vaccine developed for the trial was tailored to recognize the cancer cells present in each trial participant's pancreatic cancer tumor and stimulate the body's immune system to fight the cancer.
- "We are delighted to be collaborating with Stand Up To Cancer to fund the future of this ground-breaking research.
- The outcome of this study could represent a real turning point for pancreatic cancer," said Michelle Capobianco, president and CEO, Pancreatic Cancer North America.
- "Pancreatic cancer research is a significant focus for SU2C, accounting for over 23% of our entire cancer portfolio.